Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
Allergan · Functional Constipation
Phase 2
Completed
35
2022-04
Industry sponsor intelligence
AllerganClinical Pipeline.
Lead-sponsor view of Allergan's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 7
- Recruiting
- 0
- Active
- 0
- Completed
- 2
- Results posted
- 7
- Avg enrollment
- 313
Pipeline overview
Programs by phase and activity.
Velocity
Allergan trials by start year
Study start year · indexed snapshot
Development
Trials by phase
7phase labels
Early Phase 10
Phase 10
Phase 22
Phase 35
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Relamorelin → | 6 | 0 | 1 | 5 | 0 | 0 |
| Linaclotide → | 1 | 0 | 1 | 0 | 0 | 0 |
Active peptide trials
In motion now.
No studies in this snapshot.
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
Allergan · Diabetes Mellitus · Diabetes Mellitus Complications
Phase 2
Completed
393
2019-07
Search sponsor records
All Allergan studies.
This page groups studies where Allergan is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
7 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT04110145Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional ConstipationApr 26, 2022NCT03420781A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03Dec 22, 2021NCT03786380Diabetic Gastroparesis Study 05Dec 15, 2021NCT03383146A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04Nov 23, 2021NCT03426345Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02Aug 6, 2021NCT03285308A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01Jul 29, 2021NCT02357420Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic GastroparesisJul 24, 2019